Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna Says Interim Data Positive From Study of Covid-19 Vaccine in Children 6 to under 12

10/25/2021 | 07:07am EST

By Michael Dabaie

Moderna Inc. said it had positive interim data from the Phase 2/3 study of its Covid-19 vaccine candidate in children 6 to under 12 years of age.

The interim analysis showed a robust neutralizing antibody response after two doses of mRNA-1273 at the 50 ug dose level with a favorable safety profile, the company said Monday.

Moderna said it plans to submit these data to the U.S. Food and Drug Administration, European Medicines Agency and other global regulators in the near term.

Its shares rose 0.8% to $329.01 premarket.

The cohort enrolled 4,753 participants who were 6 to less than 12 years of age. The company said the results demonstrate strong immune response in this cohort of children one month after the second dose and met the co-primary immunogenicity objective for 6 to less than 12 years olds in its KidCOVE study.

KidCOVE is a study to evaluate the safety, tolerability, reactogenicity and effectiveness of two 50 ug doses of mRNA-1273 given to healthy children 28 days apart. The study population is divided into 3 age groups--6 to less than 12 years, 2 to less than 6 years, and 6 months to less than 2 years. Moderna on Monday reported on the 6 to under 12 years of age cohort.

MRNA-1273 was generally well tolerated with a safety and tolerability profile generally consistent with the Phase 3 COVE study in adolescents and adults, Moderna said. The majority of adverse events were mild or moderate in severity. The most common solicited adverse events were fatigue, headache, fever, and injection site pain, it said.

Moderna said safety data continue to accrue and the study continues to be monitored by an independent safety monitoring committee. All participants will be monitored for 12 months after their second injection.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

10-25-21 0907ET

All news about MODERNA, INC.
03:32aEUROPE : European stocks tumble on doubts about vaccine efficacy against Omicron
RE
03:32aEuropean stocks tumble on doubts about vaccine efficacy against Omicron
RE
03:31aDollar dives, yen jumps on Moderna CEO's Omicron warning
RE
03:28aOmicron warnings push euro zone debt yields back down
RE
03:25aDollar dives, yen jumps on Moderna CEO's Omicron warning
RE
03:21aModerna CEO Expects Lower COVID-19 Vaccine Efficacy Against Omicron Variant
MT
03:11aChina blue-chips close lower on Omicron variant, weak services data
RE
03:08aCOVAX allocates 4.7 mln AstraZeneca COVID-19 vaccine doses to N.Korea
RE
03:06aOil slumps on jitters over vaccine efficacy
RE
03:05aModerna CEO warns COVID-19 shots less effective against Omicron, spooks markets
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 14,0x
Yield 2021 -
Capitalization 149 B 149 B -
EV / Sales 2021 7,86x
EV / Sales 2022 6,16x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 368,51 $
Average target price 272,53 $
Spread / Average Target -26,0%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.252.74%149 412
LONZA GROUP AG28.41%58 671
IQVIA HOLDINGS INC.48.85%50 948
SEAGEN INC.-5.61%30 228
CELLTRION, INC.-40.81%24 321
ICON PUBLIC LIMITED COMPANY41.59%22 472